Skye Bioscience, Inc.
Skye Bioscience, Inc. (SKYE) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02 Termination of a Material Definitive Agreement. On September 8, 2026, in connection with the resignation of John P. Sharp as Chief Financial Officer and principal financial and accounting officer of Skye Bioscience, Inc., a Nevada corporation (the “Company”), the Compan
Skye Bioscience, Inc. (SKYE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously disclosed on the Current Report on Form 8-K filed by Skye Bioscience, Inc., a Nevada corporation (the “Company”), with the U.S. Securities and Exchange Commission (the “SEC”) on August 14, 2026, concurrently with
Ultragenyx (RARE) and Regeneron (REGN) received FDA approvals for GENGLYCOS and Pasatru, respectively. BioMarin (BMRN) acquired Alesta for $490M. Humacyte (HUMA) and Eyepoint (EYPT) faced trial setbacks. Key financials: RARE -$25.32, REGN -$826.64, BMRN -$67.68, HUMA -$0.68.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning SKYE (Skye Bioscience, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent SKYE coverage spans corporate actions, insider activity and mergers & acquisitions.
In the last 30 days, SKYE insiders filed 18 SEC Form 4 transactions — no purchases and 18 sales ($281K). The most active reporter was 5AM Partners VII, LLC with 9 filings.
Leadership change and contract termination may cause short‑term volatility and affect operational continuity.
Potential dilution and cash infusion could modestly support the stock price, but the limited size limits impact.
Acquisition adds a Crohn's disease program and financing of $125 million.
Insider sale by a 10% owner may signal reduced confidence, potentially pressuring the stock short term.
Insider sale may signal reduced confidence, potential short-term pressure on SKYE stock.
AlphAI scores every news story that mentions SKYE with an AI model for sentiment and relevance, and aggregates insider trades from Skye Bioscience, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Skye Bioscience, Inc. (SKYE) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02 Termination of a Material Definitive Agreement. On September 8, 2026, in connection with the resignation of John P. Sharp as Chief Financial Officer and principal financial and accounting officer of Skye Bioscience, Inc., a Nevada corporation (the “Company”), the Compan
2 min readSkye Bioscience, Inc. (SKYE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously disclosed on the Current Report on Form 8-K filed by Skye Bioscience, Inc., a Nevada corporation (the “Company”), with the U.S. Securities and Exchange Commission (the “SEC”) on August 14, 2026, concurrently with
2 min readUltragenyx (RARE) and Regeneron (REGN) received FDA approvals for GENGLYCOS and Pasatru, respectively. BioMarin (BMRN) acquired Alesta for $490M. Humacyte (HUMA) and Eyepoint (EYPT) faced trial setbacks. Key financials: RARE -$25.32, REGN -$826.64, BMRN -$67.68, HUMA -$0.68.
3 min readSchwab Andrew J. sold 375,840 indirectly-held shares of Skye Bioscience, Inc. (SKYE) at an average of $0.37 ($0.32–$0.38, $0.14M total) across 9 trades over 2026-08-18 to 2026-08-20.
1 min read5AM Partners VII, LLC sold 375,840 indirectly-held shares of Skye Bioscience, Inc. (SKYE) at an average of $0.37 ($0.32–$0.38, $0.14M total) across 9 trades over 2026-08-18 to 2026-08-20. Filed jointly with 5AM Ventures VII, L.P. (10% owner), 5AM Partners II, LLC (10% owner), 5AM Ventures II LP (10% owner), 5AM CO-INVESTORS II LP (10% owner), DIEKMAN JOHN D (10% owner), PARMAR KUSH (10% owner) and ROCKLAGE SCOTT M (10% owner).
1 min readSkye Bioscience (SKYE) will acquire Redx Pharma via a scheme of arrangement, creating Nasdaq-listed Fibrx Therapeutics led by Redx management. The lead asset is RXC008 for fibrostenotic Crohn’s, with FDA Fast Track and Phase 2 topline data expected in H2 2028. Financing totals $125M, including a $68M PIPE and $36M Series A, funding operations into 2029. SKYE closed at $0.50.
4 min readSkye Bioscience (Nasdaq: SKYE) will acquire privately held Redx Pharma via a UK scheme of arrangement, forming Fibrx Therapeutics that will trade on Nasdaq. The deal includes about $125 million in committed financings, including a ~$68 million PIPE and a $36 million Series A. Funds are expected to support RXC008 Phase 2 through 2029, with topline data in H2 2028.
4 min readSkye Bioscience, Inc. (SKYE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings • Combined company to trade on Nasdaq and operate as Fibrx Therapeutics, a fibrosis-focused company led by the Redx management team and board • Company’s lead program will be RXC008, Red
4 min readSkye Bioscience, Inc. announced that its cohort review committee has approved the opening of cohort 2 for its clinical trial. This decision was made based on favorable safety data observed in the first four participants treated in cohort 1. The company is actively developing next-generation molecules to treat obesity and related conditions, with its lead candidate, nimacimab, undergoing Phase IIa clinical trials.
2 min readSkye Bioscience, Inc. has received approval to open the second cohort of its CBeyond Part C Expansion Study, following a safety review of the first cohort. The study is evaluating nimacimab monotherapy at varying doses for obesity and metabolic health disorders. Investors have reacted positively to the news, with shares trading near their 52-week high, and the company maintains a "GREAT" Financial Health score according to InvestingPro data.
3 min read